Giulia C. Leonardi

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi et al. · JAMA Oncology · 2022 · 384 citations · Full text

Medicine, Cancer Biology, Oncology +17

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan et al. · Journal of Clinical Oncology · 2018 · 355 citations · Full text

Life Sciences, Immunology, Oncology +17

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Joshua K. Sabari, Giulia C. Leonardi, Catherine A. Shu et al. · Annals of Oncology · 2018 · 318 citations · Full text

Medicine, Cancer Biology, Oncology +17

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr et al. · Clinical Cancer Research · 2020 · 219 citations

Medicine, Molecular Genetics, Oncology +17